HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Neutral 75.1%

Neg 0% Neu 75.1% Pos 0%

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.